Breaking the channel barrier: same-fluorescence, different-Tm probe strategy enables seven-target respiratory virus detection on a six-channel PCR platform within 20 minutes

Performance and application evaluation of SARS-CoV-2 antigen assay

10.1002/jmv.27798 · doi-reference

CRISPR anti-tag-mediated room-temperature RNA detection using CRISPR/Cas13a

10.1038/s41467-025-64205-4 · doi-reference

Influenza A, influenza B, human respiratory syncytial virus and SARSCoV-2 molecular diagnostics and epidemiology in the post COVID-19 era

10.1186/s12931-024-02862-7 · doi-reference

Respiratory syncytial virus infections in adults: a narrative review

10.1016/s2213-2600(24)00255-8 · doi-reference

Lancet infectious, what is the pandemic potential of avian influenza A(H5N1)?

10.1016/s1473-3099(24)00238-x · doi-reference

Multiplex molecular assays for the laboratory-based and point-of-care diagnosis of infections caused by seasonal influenza, COVID-19, and RSV

10.1080/14737159.2024.2408745 · doi-reference

Clinical evaluation of BioFire COVID-19 test, BioFire respiratory panel 2.1, and Cepheid Xpert Xpress SARS-CoV-2 assays for sample-to-answer detection of SARS-CoV-2

10.3390/genes14010233 · doi-reference

A multicenter study to assess the performance of the point-of-care RT-PCR Cobas SARS-CoV-2 & influenza A/B nucleic acid test for use on the Cobas Liat system in comparison with centralized assays across healthcare facilities in the United States

10.1128/jcm.01459-24 · doi-reference

Clinical performance of Abbott ID NOW™ COVID-19 2.0 rapid molecular point-of-care test compared to three real-time RT-PCR assays

10.1128/spectrum.02033-24 · doi-reference

Evaluation of the analytical and clinical performance of two RT-PCR based point-of-care tests; cepheid xpert® xpress CoV-2/Flu/RSV plus and SD BioSensor STANDARD™ M10 Flu/RSV/SARS-CoV-2

10.1016/j.jcv.2024.105674 · doi-reference

Comparison of next generation diagnostic systems (NGDS) for the detection of SARS-CoV-2

10.1002/jcla.24285 · doi-reference

An ultra-sensitive, multiplexed, and cost-effective POCT system for the detection of co-infecting respiratory viruses, including SARS-CoV-2, Flu A, Flu B, and RSV, within 30 min

10.1016/j.jpba.2025.116765 · doi-reference

CRISPR-Cas12a2-Based multiplexed diagnostic for rapid and highly sensitive detection of respiratory viruses

10.1021/acs.analchem.5c07791 · doi-reference

Development of a multi-recombinase polymerase amplification assay for rapid identification of COVID-19, influenza A and B

10.1002/jmv.28139 · doi-reference

Comparison of respiratory specimen collection methods for detection of influenza virus infection by reverse Transcription-PCR: a literature review

10.1128/jcm.00027-19 · doi-reference

Culture-based virus isolation to evaluate potential infectivity of clinical specimens tested for COVID-19

10.1128/jcm.01068-20 · doi-reference

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France

10.1016/j.lanmic.2026.101353 · doi-reference

Alarming situation of emerging H5 and H7 avian influenza and effective control strategies

10.1080/22221751.2022.2155072 · doi-reference

Direct-acting antivirals for RSV treatment, a review

10.1016/j.antiviral.2024.105948 · doi-reference

Influenza

10.1016/s0140-6736(22)00982-5 · doi-reference

Influenza

10.1038/s41572-018-0002-y · doi-reference

Bacterial multiplex polymerase chain reaction tests for the diagnosis and management of pneumonia: ready for prime time?

10.1136/thorax-2024-222297 · doi-reference

Can multiplex molecular panels of microbial pathogens transform respiratory care in critically ill patients?

10.1080/14737159.2025.2527635 · doi-reference